Combination therapy with interferon alpha and beta to chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C (CHC) poses a significant global health challenge.
• Improving sustained response (SR) rates is crucial for effective CHC treatment.
• Interferon (IFN) alpha and beta are key antiviral agents, but their optimal use in combination is under investigation.

Purpose of the Study:

• To evaluate the efficacy of combination therapy with interferon (IFN) alpha and beta for increasing sustained response (SR) rates in patients with chronic hepatitis C (CHC).
• To compare the SR rates between combination therapy and single IFN alpha therapy across different CHC patient subgroups defined by HCV serotype and viral load.

Main Methods:

• Fifty CHC patients were divided into four groups based on HCV serotype (1 or 2) and HCV-RNA titer (high or low).
• Combination therapy involved daily natural IFN beta followed by thrice-weekly natural IFN alpha for 20 weeks.
• A control group of 49 CHC patients received single IFN alpha therapy.

Main Results:

• Overall SR rates showed no significant difference between combination and single therapy groups.
• However, in the HCV serotype 1 high viral load subgroup (1H), combination therapy achieved a significantly higher SR rate (67%) compared to single therapy (18%) (p<0.05).
• Specific SR rates for combination therapy were 62% (1H), 45% (1L), 70% (2H), and 86% (2L).

Conclusions:

• Combination therapy with IFN alpha and beta may be beneficial for CHC patients, particularly those with HCV serotype 1 and moderately high viral loads.
• Further research is warranted to optimize combination therapy regimens for specific CHC patient populations.